Patent · US Active

Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors

US11292796B2 · kind B2 · utility

0Cited by
23References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 4, 2020
Grant dateApr 5, 2022
Priority date—
Expiry dateMay 4, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D498/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are Heteroaryl Compounds having the following structure: Further provided herein are methods for preparing a compound of formula (I), the method comprising contacting a compound of formula (III)

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.